Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications, 17136-17137 [2011-7212]
Download as PDF
Emcdonald on DSK2BSOYB1PROD with NOTICES
17136
Federal Register / Vol. 76, No. 59 / Monday, March 28, 2011 / Notices
13. Endolymphatic Shunt Tube with
Valve,
14. Hip Joint Metal/Polymer
Constrained Cemented or Uncemented
Prosthesis,
15. Apnea Monitors,
16. Polymethylmethacrylate (PMMA)
Bone Cement,
17. Cyclosporine and Tacrolimus
Assays,
18. Transcutaneous Air Conduction
Hearing Aid System (TACHAS),
19. Intraoral Devices for Snoring and/
or Obstructive Sleep Apnea,
20. Cutaneous Carbon Dioxide and
Oxygen Monitors,
21. Knee Joint Patellofemorotibial and
Femorotibial Metal/Polymer PorousCoated Uncemented Prostheses,
22. Optical Impression Systems for
Computer Assisted Design and
Manufacturing (CAD/CAM) of Dental
Restorations,
23. Resorbable Calcium Salt Bone
Void Filler Device,
24. Surgical Sutures,
25. Breath Nitric Oxide Test,
26. Breast Lesion Documentation
System,
27. Arrhythmia Detector and Alarm,
28. Serological Reagents for the
Laboratory Diagnosis of West Nile Virus,
29. Endotoxin Assay,
30. Dental Sonography and Jaw
Tracking Devices,
31. Human Dura Mater (applicable to
dura mater recovered before May 25,
2005),
32. Hepatitis A Virus Serological
Assays,
33. Factor V Leiden DNA Mutation
Detection Systems,
34. Immunomagnetic Circulating
Cancer Cell Selection and Enumeration
System,
35. Root-form Dental Implants and
Endosseous Dental Implant Abutments,
36. Dental Base Metal Alloys,
37. Dental Noble Metal Alloys,
38. Serological Assays for the
Detection of Beta-Glucan,
39. Sirolimus Test Systems,
40. Newborn Screening Test Systems
for Amino Acids, Free Carnitine, and
Acylcarnitines Using Tandem Mass
Spectrometry,
41. Implantable Radiofrequency
Transponder System for Patient
Identification and Health Information,
42. External Penile Rigidity Devices,
43. Assisted Reproduction Laser
Systems,
44. Vascular and Neurovascular
Embolization Devices,
45. Drug Metabolizing Enzyme
Genotyping System,
46. Instrumentation for Clinical
Multiplex Test Systems,
47. Automated Fluorescence in situ
Hybridization (FISH) Enumeration
Systems,
VerDate Mar<15>2010
17:14 Mar 25, 2011
Jkt 223001
48. Dental Bone Grafting Material
Devices,
49. RNA Preanalytical Systems (RNA
Collection, Stabilization and
Purification Systems for RT–PCR used
in Molecular Diagnostic Testing),
50. Oral Rinse to Reduce the
Adhesion of Dental Plaque,
51. AFP–L3% Immunological Test
Systems,
52. CFTR Gene Mutation Detection
System,
53. Low Energy Ultrasound Wound
Cleaner,
54. Tinnitus Masker Devices,
55. Labeling for Male Condoms Made
of Natural Rubber Latex,
56. Implantable Intra-Aneurysm
Pressure Measurement System,
57. Reagents for Detection of Specific
Novel Influenza A Viruses,
58. Topical Oxygen Chamber for
Extremities,
59. Olfactory Test Device,
60. Fecal Calprotectin Immunological
Test Systems,
61. Absorbable Hemostatic Device,
62. Quality Control Material for Cystic
Fibrosis Nucleic Acid Assays,
63. Oxygen Pressure Regulators and
Oxygen Conserving Devices,
64. Herpes Simplex Virus Types 1 and
2 Serological Assays,
65. Computerized Labor Monitoring
Systems,
66. Gene Expression Profiling Test
System for Breast Cancer Prognosis,
67. Intervertebral Body Fusion Device,
68. Filtering Facepiece Respirator for
Use by the General Public in Public
Health Medical Emergencies,
69. Absorbable Poly(hydroxybutyrate)
Surgical Suture Produced by
Recombinant DNA Technology,
70. In Vitro Human
Immunodeficiency Virus (HIV) Drug
Resistance Genotype Assay,
71. Electrocardiograph Electrodes,
72. Remote Medication Management
System,
73. Automated Blood Cell Separator
Device Operating by Centrifugal or
Filtration Separation Principle,
74. Plasmodium Species Antigen
Detection Assays,
75. Full Field Digital Mammography
System,
76. Certain Percutaneous
Transluminal Coronary Angioplasty
(PTCA) Catheters,
77. Tissue Adhesive for the Topical
Approximation of Skin,
78. Bone Sonometers,
79. Tissue Expander,
80. Cord Blood Processing System and
Storage Container.
II. Electronic Access
Persons interested in obtaining a copy
of any revised special controls guidance
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
document may do so by using the
Internet. A search capability for all
CDRH guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm. To
receive any affected CDRH guidance you
may either send an email request to
dsmica@fda.hhs.gov to receive an
electronic copy of the document or send
a fax request to 301–847–8149 to receive
a hard copy.
For CBER guidances, you may send a
request to the Office of Communication,
Outreach and Development (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
suite 200N, Rockville, MD 20852–1448.
The guidance may also be obtained by
mail by calling CBER at 1–800–835–
4709 or 301–827–1800. In addition,
CBER guidance documents are available
at https://www.fda.gov/Biologics
BloodVaccines/GuidanceCompliance
RegulatoryInformation/default.htm.
III. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Authority: 21 U.S.C. 371(h).
Dated: March 23, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy,
Planning and Budget.
[FR Doc. 2011–7211 Filed 3–25–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2010–M–0519, FDA–
2010–M–0556, FDA–2010–M–0558, FDA–
2010–M–0557, and FDA–2010–M–0591]
Medical Devices; Availability of Safety
and Effectiveness Summaries for
Premarket Approval Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is publishing a
list of premarket approval applications
SUMMARY:
E:\FR\FM\28MRN1.SGM
28MRN1
17137
Federal Register / Vol. 76, No. 59 / Monday, March 28, 2011 / Notices
(PMAs) to inform the public of the
availability of safety and effectiveness
summaries of approved PMAs through
the Internet and the Agency’s Division
of Dockets Management.
Submit written requests for
copies of summaries of safety and
effectiveness data to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Please cite the appropriate docket
number as listed in table 1 of this
document when submitting a written
request. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the summaries of safety and
effectiveness.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Nicole Wolanski, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1650, Silver Spring,
MD 20993, 301–796–6570.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of January 30,
1998 (63 FR 4571), FDA published a
final rule that revised 21 CFR 814.44(d)
and 814.45(d) to discontinue individual
publication of PMA approvals and
denials in the Federal Register. Instead,
the Agency now posts this information
on the Internet on FDA’s home page at
https://www.fda.gov. FDA believes that
this procedure expedites public
notification of these actions because
announcements can be placed on the
Internet more quickly than they can be
published in the Federal Register, and
FDA believes that the Internet is
accessible to more people than the
Federal Register.
In accordance with section 515(d)(4)
and (e)(2) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C.
360e(d)(4) and (e)(2)), notification of an
order approving, denying, or
withdrawing approval of a PMA will
continue to include a notice of
opportunity to request review of the
order under section 515(g) of the FD&C
Act. The 30-day period for requesting
reconsideration of an FDA action under
§ 10.33(b) (21 CFR 10.33(b)) for notices
announcing approval of a PMA begins
on the day the notice is placed on the
Internet. Section 10.33(b) provides that
FDA may, for good cause, extend this
30-day period. Reconsideration of a
denial or withdrawal of approval of a
PMA may be sought only by the
applicant; in these cases, the 30-day
period will begin when the applicant is
notified by FDA in writing of its
decision.
The regulations provide that FDA
publish a quarterly list of available
safety and effectiveness summaries of
PMA approvals and denials that were
announced during that quarter. The
following is a list of approved PMAs for
which summaries of safety and
effectiveness were placed on the
Internet from October 1, 2010, through
December 31, 2010, and includes one
denial action during this period. The list
provides the manufacturer’s name, the
product’s generic name or the trade
name, and the date of action.
TABLE 1—LIST OF PMA ACTIVITY FROM OCTOBER 1, 2010, THROUGH DECEMBER 31, 2010
PMA No.
Docket No.
Applicant
Trade name
P100016 ...................
FDA–2010–M–0556
Aaren Scientific, Inc
P040005 (S005) .......
P980018 (S010) .......
P080009 ...................
FDA–2010–M–0558
FDA–2010–M–0557
.................................
P080018 ...................
FDA–2010–M–0591
Dako Denmark A/S
Dako Denmark A/S
Ethicon Endo-Surgery, Inc.
Carestream Health,
Inc.
EC–3 intraocular lens (IOL) and EC–3
precision aspheric lens (PAL) IOL.
HER 2 FISH PharmDx kit ........................
HercepTest kit ..........................................
SEDASYS computer-assisted personalized sedation system.
Kodak DirectView CR mammography
system.
II. Electronic Access
Persons with access to the Internet
may obtain the documents at https://
www.fda.gov/cdrh/pmapage.html.
Dated: March 23, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy,
Planning and Budget.
[FR Doc. 2011–7212 Filed 3–25–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Emcdonald on DSK2BSOYB1PROD with NOTICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Pregnancy and Prescription
Medication Use Symposium
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of meeting.
VerDate Mar<15>2010
17:14 Mar 25, 2011
Jkt 223001
The Food and Drug Administration
(FDA) is announcing the following
meeting: Pregnancy and Prescription
Medication Use Symposium. The topic
to be discussed is ‘‘Prescription Drug
Use in Pregnancy.’’
Date and Time: The meeting will be
held on May 17, 2011, from 8 a.m. to
4:30 p.m.
Location: The meeting will be held at
FDA White Oak Campus, 10903 New
Hampshire Ave., Building 31
Conference Center, the Great Room (rm.
1503), Silver Spring, MD 20993–0002.
Contact: Monica Yu, Office of
Women’s Health (OWH), Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, rm. 2313, 301–796–9449,
e-mail: monica.yu@fda.hhs.gov.
Registration: There is no registration
fee, but seating is limited to 100. Send
registration information (including
name, title, firm name, address,
telephone number, and e-mail address),
to the following registration link by May
10, 2011: https://
PO 00000
Frm 00035
Fmt 4703
Sfmt 9990
Date of action
Approved October 19, 2010.
Approved October 20, 2010.
Approved October 20, 2010.
Denied October 27, 2010.
Approved November 3, 2010.
www.accessdata.fda.gov/scripts/email/
oc/pregnancysymposium.cfm.
If you need special accommodations
due to a disability, please contact
Monica Yu at least 7 days in advance.
Visitor parking: Please see https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
SUPPLEMENTARY INFORMATION:
Transcripts: There will not be any
transcripts; however, the speakers’
Power Point presentations will be
posted on the FDA/OWH Web site after
the meeting at: https://www.fda.gov/
ForConsumers/byAudience/ForWomen/
default.htm.
Dated: March 23, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy,
Planning and Budget.
[FR Doc. 2011–7215 Filed 3–25–11; 8:45 am]
BILLING CODE 4160–01–P
E:\FR\FM\28MRN1.SGM
28MRN1
Agencies
[Federal Register Volume 76, Number 59 (Monday, March 28, 2011)]
[Notices]
[Pages 17136-17137]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-7212]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA-2010-M-0519, FDA-2010-M-0556, FDA-2010-M-0558, FDA-
2010-M-0557, and FDA-2010-M-0591]
Medical Devices; Availability of Safety and Effectiveness
Summaries for Premarket Approval Applications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is publishing a list of
premarket approval applications
[[Page 17137]]
(PMAs) to inform the public of the availability of safety and
effectiveness summaries of approved PMAs through the Internet and the
Agency's Division of Dockets Management.
ADDRESSES: Submit written requests for copies of summaries of safety
and effectiveness data to the Division of Dockets Management (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Please cite the appropriate docket number as listed in table
1 of this document when submitting a written request. See the
SUPPLEMENTARY INFORMATION section for electronic access to the
summaries of safety and effectiveness.
FOR FURTHER INFORMATION CONTACT: Nicole Wolanski, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993, 301-796-
6570.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of January 30, 1998 (63 FR 4571), FDA
published a final rule that revised 21 CFR 814.44(d) and 814.45(d) to
discontinue individual publication of PMA approvals and denials in the
Federal Register. Instead, the Agency now posts this information on the
Internet on FDA's home page at https://www.fda.gov. FDA believes that
this procedure expedites public notification of these actions because
announcements can be placed on the Internet more quickly than they can
be published in the Federal Register, and FDA believes that the
Internet is accessible to more people than the Federal Register.
In accordance with section 515(d)(4) and (e)(2) of the Federal
Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and
(e)(2)), notification of an order approving, denying, or withdrawing
approval of a PMA will continue to include a notice of opportunity to
request review of the order under section 515(g) of the FD&C Act. The
30-day period for requesting reconsideration of an FDA action under
Sec. 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a
PMA begins on the day the notice is placed on the Internet. Section
10.33(b) provides that FDA may, for good cause, extend this 30-day
period. Reconsideration of a denial or withdrawal of approval of a PMA
may be sought only by the applicant; in these cases, the 30-day period
will begin when the applicant is notified by FDA in writing of its
decision.
The regulations provide that FDA publish a quarterly list of
available safety and effectiveness summaries of PMA approvals and
denials that were announced during that quarter. The following is a
list of approved PMAs for which summaries of safety and effectiveness
were placed on the Internet from October 1, 2010, through December 31,
2010, and includes one denial action during this period. The list
provides the manufacturer's name, the product's generic name or the
trade name, and the date of action.
Table 1--List of PMA Activity From October 1, 2010, Through December 31, 2010
--------------------------------------------------------------------------------------------------------------------------------------------------------
PMA No. Docket No. Applicant Trade name Date of action
--------------------------------------------------------------------------------------------------------------------------------------------------------
P100016........................... FDA-2010-M-0556...... Aaren Scientific, Inc EC-3 intraocular lens Approved October 19, 2010.
(IOL) and EC-3 precision
aspheric lens (PAL) IOL.
P040005 (S005).................... FDA-2010-M-0558...... Dako Denmark A/S..... HER 2 FISH PharmDx kit.... Approved October 20, 2010.
P980018 (S010).................... FDA-2010-M-0557...... Dako Denmark A/S..... HercepTest kit............ Approved October 20, 2010.
P080009........................... ..................... Ethicon Endo-Surgery, SEDASYS computer-assisted Denied October 27, 2010.
Inc. personalized sedation
system.
P080018........................... FDA-2010-M-0591...... Carestream Health, Kodak DirectView CR Approved November 3, 2010.
Inc. mammography system.
--------------------------------------------------------------------------------------------------------------------------------------------------------
II. Electronic Access
Persons with access to the Internet may obtain the documents at
https://www.fda.gov/cdrh/pmapage.html.
Dated: March 23, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2011-7212 Filed 3-25-11; 8:45 am]
BILLING CODE 4160-01-P